ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Early Prophylactic-Dose Thromboprophylaxis and 30-Day Mortality in Solid Tumor Patients Hospitalized for COVID-19: A Multicenter Retrospective Cohort Study.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivePatients with solid tumors are at increased risk of venous thromboembolism (VTE), and COVID-19 infection may further enhance thrombotic risk. Although prophylactic-dose thromboprophylaxis is recommended for hospitalized patients with COVID-19 when bleeding risk is acceptable, its clinical impact among patients with solid tumors remains uncertain.MethodsWe conducted a multicenter retrospective cohort study across three tertiary hospitals in China from December 2022 to January 2023. Adult patients with solid tumors hospitalized for laboratory-confirmed COVID-19 were included. Patients receiving prophylactic-dose thromboprophylaxis within 24 hours of admission were classified as the early cohort, whereas those initiating prophylaxis after 24 hours or receiving no prophylaxis were classified as the non-early cohort. The primary outcome was 30-day mortality. Secondary outcomes included thrombotic events, bleeding events, and 60-day mortality. Multivariable Cox regression, inverse probability of treatment weighting (IPTW) analyses, multiple imputation, and sensitivity analyses were performed.ResultsAmong 431 patients, 86 were classified into the early cohort and 345 into the non-early cohort. Early prophylactic-dose thromboprophylaxis was not significantly associated with 30-day mortality (adjusted HR=1.468, 95% CI 0.840-2.567, P=0.173) or 60-day mortality (adjusted HR=1.386, 95% CI 0.798-2.408, P=0.241). IPTW-adjusted analyses and sensitivity analyses yielded consistent results. No significant associations were observed between early thromboprophylaxis and thrombotic or bleeding events.ConclusionsIn this multicenter cohort of patients with solid tumors hospitalized for COVID-19, early prophylactic-dose thromboprophylaxis was not clearly associated with improved 30-day or 60-day mortality. Further prospective studies are needed to identify patients who may benefit from optimized thromboprophylaxis strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.